KRTX - Karuna Therapeutics EPS beats by $0.03

Karuna Therapeutics (KRTX): Q4 GAAP EPS of -$0.89 beats by $0.03.Cash, cash equivalents and available-for-sale investments of $322.33M.CEO comment :“Looking ahead, 2021 is expected to be a year of execution and expansion for Karuna, as we anticipate having comprehensive registrational EMERGENT program for schizophrenia underway within the first half of the year, initiating a Phase 2 trial evaluating KarXT in adults with schizophrenia who inadequately respond to standard of care in the second half of 2021, and exploring KarXT’s potential to treat dementia-related psychosis pending results from the third cohort of our ongoing Phase 1b dose-ranging trial in healthy elderly volunteers,” Dr. Paul commented further. “These milestones and activities represent great progress in our journey to potentially deliver a completely novel treatment for those living with schizophrenia and other serious neuropsychiatric conditions.”Press Release

For further details see:

Karuna Therapeutics EPS beats by $0.03